Peapod Lane Capital LLC Acquires New Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Peapod Lane Capital LLC purchased a new stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 328,581 shares of the company's stock, valued at approximately $1,101,000. Peapod Lane Capital LLC owned about 0.39% of Atea Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in AVIR. BML Capital Management LLC raised its stake in shares of Atea Pharmaceuticals by 4.3% in the third quarter. BML Capital Management LLC now owns 6,650,000 shares of the company's stock worth $22,278,000 after acquiring an additional 274,379 shares during the last quarter. FMR LLC increased its holdings in shares of Atea Pharmaceuticals by 2.8% in the third quarter. FMR LLC now owns 6,618,297 shares of the company's stock valued at $22,171,000 after purchasing an additional 182,174 shares in the last quarter. State Street Corp raised its position in Atea Pharmaceuticals by 0.7% in the 3rd quarter. State Street Corp now owns 1,733,486 shares of the company's stock worth $5,807,000 after purchasing an additional 11,566 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Atea Pharmaceuticals by 8.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 650,157 shares of the company's stock worth $2,178,000 after buying an additional 50,794 shares in the last quarter. Finally, Barclays PLC boosted its position in Atea Pharmaceuticals by 74.5% in the 3rd quarter. Barclays PLC now owns 177,077 shares of the company's stock valued at $593,000 after buying an additional 75,624 shares during the last quarter. Institutional investors and hedge funds own 86.67% of the company's stock.

Atea Pharmaceuticals Price Performance

Shares of AVIR stock traded up $0.04 on Monday, reaching $3.15. 203,336 shares of the stock were exchanged, compared to its average volume of 419,809. Atea Pharmaceuticals, Inc. has a one year low of $2.75 and a one year high of $4.60. The stock has a market cap of $266.05 million, a PE ratio of -1.52 and a beta of 0.19. The stock has a 50 day moving average price of $3.17 and a 200 day moving average price of $3.39.

Insider Buying and Selling

In other news, Director Franklin M. Berger sold 359,606 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total value of $1,024,877.10. Following the transaction, the director now owns 451,897 shares of the company's stock, valued at $1,287,906.45. This represents a 44.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 17.80% of the company's stock.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.